Last updated: August 25, 2026
Horizon Medicines LLC sued Alkem Laboratories Ltd. in the U.S. District Court for the District of Delaware after Alkem filed an abbreviated new drug application seeking approval for a generic version of Vimovo, a delayed-release combination of naproxen and esomeprazole magnesium. The case concerned Orange Book-listed patents covering the product’s dual-release formulation. The dispute was an ANDA patent case under the Hatch-Waxman Act and did not produce a public merits judgment invalidating the asserted Vimovo patents. The docket ultimately closed through a settlement-related dismissal.
What drug and patents were at issue in Horizon v. Alkem?
The case involved Vimovo, approved by the FDA under NDA 022511. Vimovo combines:
| Component |
Function |
| Naproxen |
Nonsteroidal anti-inflammatory drug |
| Esomeprazole magnesium |
Proton-pump inhibitor intended to reduce naproxen-associated gastric risk |
The product uses a formulation designed to release esomeprazole before naproxen. That sequence is central to the product’s patent position and distinguishes Vimovo from an ordinary co-packaged or immediately released combination.
Horizon asserted patents listed in the FDA Orange Book for Vimovo. The principal patent family associated with the litigation included:
| Patent |
General subject matter |
Relevance |
| U.S. Patent No. 6,926,907 |
Pharmaceutical compositions combining a proton-pump inhibitor with an NSAID |
Core combination and release-profile protection |
| U.S. Patent No. 8,557,993 |
Formulation and dosage-form technology for naproxen and esomeprazole |
Later-generation formulation protection |
The complaint alleged that Alkem’s proposed generic product would infringe the asserted claims upon commercial manufacture, use, or sale. The action was filed under the statutory framework allowing an NDA holder or patent owner to sue after receiving a Paragraph IV certification. [1][2]
When was the Horizon v. Alkem case filed, and where?
Horizon filed the action in 2018 in the District of Delaware under case number 1:18-cv-01014. The case was assigned to Judge Richard G. Andrews.
| Case element |
Detail |
| Plaintiff |
Horizon Medicines LLC |
| Defendant |
Alkem Laboratories Ltd. |
| Court |
U.S. District Court for the District of Delaware |
| Case number |
1:18-cv-01014 |
| Case type |
Hatch-Waxman ANDA patent litigation |
| Reference product |
Vimovo |
| Active ingredients |
Naproxen and esomeprazole magnesium |
| Regulatory trigger |
Alkem ANDA and Paragraph IV patent certification |
| Judicial outcome |
Settlement-related dismissal; no public merits invalidity judgment |
The use of an ANDA pathway limited the immediate economic remedy available to Horizon. A successful infringement action would generally result in an order delaying FDA approval of Alkem’s ANDA until expiration of the relevant patents or another legally effective date. [3]
What patents protected Vimovo against Alkem’s generic?
The asserted Vimovo patents protected the product at the formulation level rather than merely claiming naproxen or esomeprazole as individual active ingredients.
U.S. Patent No. 6,926,907
The ’907 patent covered pharmaceutical compositions containing an NSAID and a proton-pump inhibitor arranged to provide different release characteristics. The patent’s commercial value came from protecting the combination architecture used by Vimovo.
The patent had a statutory expiration in the 2020s, subject to any applicable patent-term adjustment or extension. Its remaining life at the time of the 2018 filing created a meaningful barrier to an immediate generic launch.
U.S. Patent No. 8,557,993
The ’993 patent addressed later formulation claims associated with the delayed-release combination. Such claims are often more difficult to design around when they recite specific dosage-form structures, separation of active ingredients, enteric protection, or staged release.
The ’993 patent extended the effective patent barrier beyond the earliest Vimovo composition patent. Its presence increased the likelihood that a generic applicant would need either a successful validity or noninfringement position, a settlement with a licensed launch date, or a product redesign.
What was Alkem’s Paragraph IV challenge?
Alkem’s ANDA filing necessarily required it to address the patents listed for Vimovo in the Orange Book. The Paragraph IV position would have asserted one or more of the following:
- The asserted claims were not infringed by Alkem’s proposed product.
- The asserted claims were invalid for anticipation, obviousness, lack of written description, lack of enablement, or another statutory ground.
- The patents were unenforceable, if Alkem had a legally supportable inequitable-conduct theory.
Horizon’s complaint converted the certification into a statutory act of infringement under 35 U.S.C. § 271(e)(2). The litigation therefore focused on the hypothetical commercial characteristics of Alkem’s ANDA product, not on proof that Alkem had already sold a competing product. [1][3]
The public docket does not show a final trial judgment holding the asserted patents invalid or finding that Alkem’s ANDA product did not infringe. The absence of a merits judgment means the case did not establish a binding public precedent on the scope or validity of the Vimovo claims.
What was the litigation outcome and settlement status?
The case ended without a publicly reported merits decision that cancelled the asserted patent barrier. The docket reflects a dismissal associated with settlement.
Settlement agreements in Hatch-Waxman cases commonly address:
- The date on which the generic company may launch.
- Whether the generic receives an authorized-generic arrangement or supply right.
- Restrictions on the product’s formulation, labeling, or indications.
- Treatment of later-issued patents.
- Covenants not to sue and releases.
- Allocation of litigation costs and attorneys’ fees.
The public case docket does not disclose the commercial terms of the Horizon-Alkem settlement. The dismissal therefore does not establish that Alkem prevailed on validity or infringement. It indicates that the parties resolved the dispute without a public adjudication on those issues.
What is the Orange Book status of Vimovo?
Vimovo was approved by the FDA as a prescription delayed-release tablet. Its Orange Book protection was based on formulation and combination patents rather than regulatory exclusivity alone.
| Regulatory issue |
Assessment |
| FDA approval |
Vimovo approved under NDA 022511 |
| Dosage form |
Delayed-release tablet |
| Combination |
Naproxen and esomeprazole magnesium |
| Orange Book listing |
Patent listings associated with Vimovo’s formulation |
| Generic pathway |
ANDA |
| Litigation mechanism |
Paragraph IV Hatch-Waxman action |
| Exclusivity significance |
Patent protection was more important than remaining new-drug exclusivity by the time of the lawsuit |
FDA approval of an ANDA does not eliminate patent barriers. An ANDA applicant may obtain approval subject to a delayed effective date, depending on the patents listed, certification history, court decisions, settlement terms, and any regulatory exclusivity still in force. [2]
When does Vimovo lose patent exclusivity?
The earliest Vimovo patent protection was scheduled to expire before or during the 2020s, while later formulation patents extended protection beyond the earliest patent term. The relevant commercial date was therefore not simply the expiration of the oldest patent.
For generic-entry analysis, the controlling questions are:
- Which patents remained listed at the time of ANDA approval?
- Which patents were asserted against the specific applicant?
- Did the settlement provide an agreed launch date?
- Were later-issued or continuation patents relevant?
- Did any pediatric exclusivity or patent-term adjustment affect the effective date?
A generic company could launch before the latest listed patent expiration only if it obtained a favorable judgment, prevailed on a Paragraph IV dispute, reached a license or settlement permitting earlier entry, or relied on a legally supportable noninfringement position.
How strong was Horizon’s Vimovo patent estate?
Horizon’s patent position was commercially meaningful but structurally exposed to the normal risks of combination-product litigation.
Strengths
- The patents targeted the product’s distinctive staged-release architecture.
- The claims were directed to a marketed dosage form rather than a purely conceptual combination.
- Multiple patent generations created overlapping protection.
- The formulation was difficult to replicate while preserving the same release sequence and therapeutic profile.
- An ANDA applicant faced a statutory stay of FDA approval for up to 30 months after the relevant Paragraph IV notice, subject to statutory exceptions. [3]
Risks
- Combination and formulation patents are vulnerable to obviousness attacks based on known NSAID and proton-pump-inhibitor technologies.
- Claim construction could materially affect whether the generic’s release profile fell within the asserted claims.
- The earliest patent expiration reduced the duration of the exclusivity window.
- A generic applicant could attempt a formulation design-around.
- Patent settlements can authorize entry before the last nominal patent expiration, reducing the value of later patents.
The litigation outcome preserved the commercial relevance of the patent estate without generating a public appellate or district-court ruling confirming broad claim validity.
What generic launch risks did the settlement create?
The principal risk to Horizon was an authorized or licensed Alkem launch before the expiration of every patent listed for Vimovo. The principal risk to Alkem was delayed approval and exposure to an injunction if Horizon prevailed.
| Launch scenario |
Effect on Horizon |
Effect on Alkem |
| Launch after final patent expiration |
Full erosion risk at expiration |
Lowest litigation risk |
| Settlement-permitted early launch |
Earlier price erosion |
Controlled entry with reduced damages risk |
| Trial victory for Horizon |
Patent barrier preserved |
ANDA approval delayed |
| Trial victory for Alkem |
Potential immediate or early entry |
Rapid market access |
| Formulation design-around |
Reduced protection from asserted claims |
Additional development and regulatory cost |
Because the settlement terms are not publicly disclosed, the permitted launch date and any restrictions on Alkem’s product cannot be determined from the public docket alone.
Which companies challenged Vimovo patents?
The Alkem action was part of the broader generic-entry risk surrounding Vimovo. Other generic manufacturers could pursue separate ANDAs and bring separate Paragraph IV litigation. Each case required a product-specific analysis because the outcome depended on the applicant’s formulation, labeling, certification language, and asserted defenses.
A settlement with Alkem would not automatically resolve challenges by other ANDA applicants. It also would not necessarily prevent another company from litigating the same Orange Book patents, unless the relevant patent claims had expired, been cancelled, or been finally adjudicated.
Does biosimilar risk apply to Vimovo?
No. Vimovo is a small-molecule combination product, not a biologic. The relevant competitive pathway is an ANDA for a generic drug under section 505(j) of the Federal Food, Drug, and Cosmetic Act, not a biosimilar application under the Public Health Service Act.
The competitive risks are therefore:
- Paragraph IV patent challenges.
- Abbreviated approval based on bioequivalence.
- Formulation design-arounds.
- Authorized-generic competition.
- Multiple generic entrants after patent expiry.
What patent litigation affects Vimovo’s commercial value?
The Horizon-Alkem case affected the timing and certainty of generic competition. It did not create a reported legal rule that broadly invalidated Horizon’s patent estate. Its business significance lies in the settlement resolution and the resulting uncertainty over Alkem’s permitted entry date.
Vimovo’s commercial exposure depended on the number of approved or pending ANDAs, the strength of the remaining formulation patents, the settlement dates granted to challengers, and the ability of generic manufacturers to reproduce the product’s delayed-release profile at scale.
Key Takeaways
- Horizon sued Alkem in the District of Delaware in 2018 over an ANDA for generic Vimovo.
- The product is a delayed-release naproxen and esomeprazole magnesium tablet.
- The dispute centered on Orange Book-listed formulation patents, including U.S. Patent Nos. 6,926,907 and 8,557,993.
- Alkem’s challenge was brought through the Paragraph IV Hatch-Waxman framework.
- The case ended through a settlement-related dismissal rather than a public merits judgment.
- The settlement terms and any authorized launch date were not disclosed in the public docket.
- Vimovo is a small-molecule combination drug, so biosimilar law does not apply.
- The principal commercial risk was generic entry through an agreed settlement date or after expiration of the remaining formulation patents.
FAQs About Horizon Medicines LLC v. Alkem Laboratories Ltd.
Was Horizon v. Alkem a patent infringement case?
Yes. It was a Hatch-Waxman patent infringement action triggered by Alkem’s ANDA and Paragraph IV certification concerning generic Vimovo.
Did Alkem invalidate Horizon’s Vimovo patents?
No public merits judgment in the case invalidated the asserted patents. The action ended through settlement-related dismissal.
What product did Alkem seek to commercialize?
Alkem sought approval for a generic delayed-release combination of naproxen and esomeprazole magnesium, the active ingredients in Vimovo.
Is Vimovo protected by method-of-use patents?
The central public patent issues in the action concerned combination and formulation protection. Method-of-use claims, if listed or separately asserted, must be analyzed independently from the formulation patents.
Could Alkem launch before all Vimovo patents expired?
Yes, if the parties’ settlement authorized an earlier launch or if Alkem obtained a favorable resolution on infringement or validity. The public docket does not disclose the settlement’s launch provisions.
References
-
U.S. District Court for the District of Delaware. (2018). Horizon Medicines LLC v. Alkem Laboratories Ltd., No. 1:18-cv-01014. Court docket.
-
U.S. Food and Drug Administration. (n.d.). Orange Book: Approved drug products with therapeutic equivalence evaluations. FDA.
-
U.S. Food and Drug Administration. (n.d.). Abbreviated new drug application process and patent certifications. FDA.
